|  |  |  |  |
| --- | --- | --- | --- |
| Disease Type | Phase I (5) | Phase II (44) | Overall (49) |
| Leukaemia | 1 (20) | 6 (13.6) | 7 (14.3) |
| Neuroblastoma | 0 | 14 (31.8) | 14 (28.6) |
| Sarcoma | 1 (20) | 12 (27.3) | 13 (26.5) |
| High Grade Glioma | 3 (60) | 12 (27.3) | 15 (30.6) |
| Total | 5 (100) | 44 (100) | 49 (100) |

Supplementary Table 1. Patients Recruited

|  |  |
| --- | --- |
| No. Weeks Treatment | Disease Type |
| **Leukaemia (7)** | **Neuroblastoma (12)** | **Sarcoma (13)** | **High Grade Glioma (13)** |
| Mean (sd) | 4.1 (3.5) | 8.8 (10.6) | 12.7 (13.4) | 10.8 (17.5) |
| Median | 2 | 7 | 7 | 6 |
| Range | 1, 10 | 1, 40 | 2, 41 | 2, 68 |

Supplementary Table 2. Treatment Weeks: Summary Statistics by Group

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Disease Type | No. patients | Median Overall Survival in months (95%CI) | Estimated 6-month Overall Survival Probability (95%CI) | Estimated 12-month Overall Survival Probability (95%CI) |
| Leukaemia | 7 |  1.3 (0.5 – 4.5) | 0.14 (0.007 – 0.46) | N/A |
| Neuroblastoma | 12 |  2.9 (0.95 − ) | 0.50 (0.21 – 0.74) | 0.33 (0.10 – 0.59) |
| Sarcoma | 13 |  3.5 (1.6 – 6.8) | 0.31 (0.09 – 0.55) | 0.15 (0.02 – 0.39) |
| High Grade Glioma | 13 |  2.2 (1.3 – 4.5) | 0.15 (0.02 – 0.39) | N/A |
| Overall | 45 |  2.7 (2.2 – 4.5) | 0.29 (0.17 – 0.42) | 0.16 (0.07 – 0.28) |

Supplementary Table 3. Overall Survival: Estimates by Disease Group

Supplementary Table 4. Progression-Free Survival: Estimates by Disease Group

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Disease Type | No. patients | Median Progression-FreeSurvival in months (95%CI) | Estimated 6-month Progression-Free Survival Probability (95%CI) | Estimated 12-month Progression-Free Survival Probability (95%CI) |
| Leukaemia | 7 |  1.1 (0.5 – 1.7) |  N/A | N/A |
| Neuroblastoma | 12 |  1.8 (0.6 – 2.1) |  0.17 (0.03 – 0.41) | N/A |
| Sarcoma | 13 |  1.8 (0.9 – 1.9) |  0.15 (0.02 – 0.39) | N/A |
| High GradeGlioma | 13 |  1.5 (0.7 – 2) |  0.15 (0.02 – 0.39) | 0.08 (0.005 – 0.29) |
| Overall | 45 |  1.6 (1 – 1.8) |  0.13 (0.05 – 0.25) | 0.03 (0.008 – 0.13) |

Supplementary Table 5. Number of Serious Adverse Events by Toxicity and Grade

|  |  |
| --- | --- |
|  | Grade |
| 1 | 2 | 3 | 4 | 5 |
| Toxicity (No. events (No. patients that experienced toxicity) |
| Blood and lymphatic system disorders |
| Cardiac arrest | 0 | 0 | 0 | 0 | 1 (1) |
| Cardiac disorders |
| Atrial ectopics | 1 (1) | 0 | 0 | 0 | 0 |
| Sinus tachycardia | 0 | 1 (1) | 0 | 0 | 0 |
| Gastrointestinal disorders |
| Diarrhoea  | 1 (1) | 0 | 0 | 0 | 0 |
| Nausea  | 1 (1) | 0 | 0 | 0 | 0 |
| Vomiting | 0 | 1 (1) | 1 (1) | 0 | 0 |
| General disorders and administration site conditions  |
| Fever | 11 (9) | 1 (1) | 0 | 0 | 0 |
| Infusion related reaction | 0 | 1 (1) | 0 | 0 | 0 |
| Immune system disorders |
| Allergic reaction | 0 | 1 (1) | 0 | 0 | 0 |
| Infections and infestations |
| Sepsis | 0 | 0 | 0 | 1 (1) | 0 |
| Upper respiratory infection | 0 | 0 | 1 (1) | 0 | 0 |
| Urinary tract infection | 0 | 0 | 1 (1) | 0 | 0 |
| Bacteraemia | 0 | 1 (1) | 0 | 0 | 0 |
| Musculoskeletal and connective tissue disorders |
| Bone pain | 0 | 1 (1) | 0 | 0 | 0 |
| Neck pain | 0 | 1 (1) | 0 | 0 | 0 |
| Nervous system disorders |
| Headache | 0 | 0 | 1 (1) | 0 | 0 |
| Seizure | 0 | 1 (1) | 1 (1) | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders |
| Distress due to fluid overload | 0 | 0 | 0 | 1 (1) | 0 |
| Dyspnea  | 0 | 0 | 0 | 5 (3) | 0 |
| Respiratory arrest | 0 | 0 | 0 | 1 (1) | 0 |

Table 6: Number of Serious Adverse Events related to treatment

|  |  |
| --- | --- |
|  | Grade |
| 1 | 2 | 3 | 4 | 5 |
| Toxicity (No. events (No. patients that experienced toxicity) |
| Immune system disorders |
| Allergic reaction | 0 | 1 (1) | 0 | 0 | 0 |
| Nervous system disorders |
| Seizure | 0 | 1 (1) | 0 | 0 | 0 |

Supplementary Table 7: Number of Adverse Events by Toxicity and Grade

|  |  |
| --- | --- |
|  | Grade |
| 1 | 2 | 3 | 4 | 5 |
| Toxicity (No. events (No. patients that experienced toxicity) |
| Blood and lymphatic system disorders |
| Anaemia | 40 (21) | 20 (12) | 15 (10) | 1 (1) | 0 |
| Platelet count decreased | 17 (9) | 8 (3) | 18 (7) | 17 (9) | 0 |
| White blood cell count decreased | 34 (15) | 12 (8) | 9 (5) | 2 (2) | 0 |
| Neutrophil count decreased | 6 (4) | 11 (7) | 15 (7) | 6 (4) | 0 |
| Haematocrit decreased | 22 (14) | 0 | 0 | 0 | 0 |
| Neutrophil count increased | 16 (8) | 0 | 1 (1) | 0 | 0 |
| Red blood cell count decreased | 15 (9) | 0 | 0 | 0 | 0 |
| Platelet count increased | 8 (5) | 0 | 0 | 0 | 0 |
| White blood cell count increased | 6 (3) | 0 | 0 | 0 | 0 |
| Febrile neutropenia | 1 (1) | 0 | 4 (4) | 0 | 0 |
| Red blood cell count increased | 2 (1) | 0 | 0 | 0 | 0 |
| Hypertension  | 0 | 2 (1) | 0 | 0 | 0 |
| Leukocytosis  | 0 | 0 | 1 (1) | 0 | 0 |
| Enlarged lymph node  | 0 | 1 (1) | 0 | 0 | 0 |
| Haematocrit increased | 1 (1) | 0 | 0 | 0 | 0 |
| Cardiac disorders |
| Tachycardia | 5 (2) | 1 (1) | 0 | 0 | 0 |
| Sinus tachycardia | 3 (3) | 2 (2) | 0 | 0 | 0 |
| Cardiac arrest | 0 | 0 | 0 | 0 | 1 (1) |
| Ear and labyrinth disorders |
| Ear pain | 1 (1) | 0 | 0 | 0 | 0 |
| Buzzing in left ear | 1 (1) | 0 | 0 | 0 | 0 |
| Endrocrine disorders |
| Cushingoid  | 1 (1) | 0 | 0 | 0 | 0 |
| TSH level decreased | 1 (1) | 0 | 0 | 0 | 0 |
| FSH level decreased | 1 (1) | 0 | 0 | 0 | 0 |
| Adrenal insufficiency  | 0 | 0 | 1 (1) | 0 | 0 |
| LH level decreased | 1 (1) | 0 | 0 | 0 | 0 |
| Hypoparathyroidism  | 0 | 1 (1) | 0 | 0 | 0 |
| Eye disorders |
| Optic nerve disorder | 0 | 1 (1) | 0 | 0 | 0 |
| Blurred vision  | 0 | 1 (1) | 0 | 0 | 0 |
| Papilledema  | 1 (1) | 0 | 0 | 0 | 0 |
| Gastrointestinal disorders |
| Vomiting  | 27 (13) | 5 (5) | 1 (1) | 0 | 0 |
| Constipation  | 9 (7) | 10 (8) | 0 | 0 | 0 |
| Nausea  | 10 (5) | 7 (6) | 0 | 0 | 0 |
| Diarrhoea  | 4 (4) | 4 (3) | 0 | 0 | 0 |
| Dysphagia  | 0 | 2 (1) | 4 (4) | 0 | 0 |
| Abdominal pain | 3 (2) | 0  | 2 (2) | 0 | 0 |
| Stomach pain | 3 (3) | 0 | 0 | 0 | 0 |
| Oral pain | 0 (0) | 2 (1) | 0 | 0 | 0 |
| Dyspepsia  | 1 (1) | 1 (1) | 0 | 0 | 0 |
| Dry mouth | 1 (1) | 0 | 0 | 0 | 0 |
| Blood in stool | 0 (0) | 1 (1) | 0 | 0 | 0 |
| Dental caries | 1 (1) | 0 | 0 | 0 | 0 |
| Bloating  | 1 (1) | 0 | 0 | 0 | 0 |
| Enterocolitis  | 0  | 1 (1) | 0 | 0 | 0 |
| Soft stool  | 1 (1) | 0 | 0 | 0 | 0 |
| Crohn’s disease | 0 | 1 (1) | 0 | 0 | 0 |
| Hypersalivation  | 0 | 1 (1) | 0 | 0 | 0 |
| General disorders and administration site conditions  |
| Fever | 30 (16) | 2 (2) | 1 (1) | 0 | 0 |
| Pain  | 7 (6) | 8 (6) | 8 (8) | 0 | 0 |
| Fatigue  | 7 (6) | 2 (2) | 0 | 0 | 0 |
| Runny nose | 4 (2) | 0 | 0 | 0 | 0 |
| Gait disturbance | 1 (1) | 1 (1) | 0 | 0 | 0 |
| Weakness  | 0 | 1 (1) | 0 | 0 | 0 |
| Common cold | 1 (1) | 0 | 0 | 0 | 0 |
| Hypothermia  | 0 | 1 (1) | 0 | 0 | 0 |
| Non-cardiac chest pain | 1 (1) | 0 | 0 | 0 | 0 |
| Chills  | 1 (1) | 0 | 0 | 0 | 0 |
| Coryzal symptoms | 1 (1) | 0 | 0 | 0 | 0 |
| Night sweats | 1 (1) | 0 | 0 | 0 | 0 |
| Excess transpiration  | 1 (1) | 0 | 0 | 0 | 0 |
| Localised oedema  | 1 (1) | 0 | 0 | 0 | 0 |
| Oedema trunk | 0 | 1 (1) | 0 | 0 | 0 |
| Immune system disorders |
| Allergic reaction | 1 (1) | 1 (1) | 1 (1) | 0 | 0 |
| Infections and infestations |
| Urinary tract infection | 0 | 0 | 4 (1) | 0 | 0 |
| Upper respiratory infection | 2 (2) | 1 (1) |  1 (1) | 0 | 0 |
| Sepsis | 0 | 0 | 3 (1) | 0 | 0 |
| COVID-19 | 2 (2) | 0 | 0 | 0 | 0 |
| Oral fungal infection | 1 (1) | 1 (1) | 0 | 0 | 0 |
| Common cold | 1 (1) | 1 (1) | 0 | 0 | 0 |
| Rhinovirus  | 0 | 0 | 1 (1) | 0 | 0 |
| Blood – staphylococcus epidermis  | 0 | 0 | 1 (1) | 0 | 0 |
| Unknown viral cough | 1 (1) | 0 | 0 | 0 | 0 |
| Bacteraemia | 0 | 0 | 1 (1) | 0 | 0 |
| Nail infection | 0 |  1 (1) | 0 | 0 | 0 |
| Bacillus cereus | 0 | 0 | 1 (1) | 0 | 0 |
| Conjunctivitis  | 1 (1) | 0 | 0 | 0 | 0 |
| Hand foot and mouth | 0 | 1 (1) | 0 | 0 | 0 |
| Herpetic lip lesions | 0 | 1 (1) | 0 | 0 | 0 |
| Injury, poisoning and procedural complications |
| Bruising  | 2 (2) | 1 (1) | 0 | 0 | 0 |
| Investigations  |
| Lymphocyte count decreased | 28 (15) | 16 (13) | 7 (7) | 2 (2) | 0 |
| Alanine aminotransferase increased | 22 (15) | 2 (2) | 1 (1) | 1 (1) | 0 |
| Aspartate aminotransferase increased | 16 (11) | 2 (1) | 3 (1) | 0 | 0 |
| Creatinine decreased | 19 (8) | 0 | 0 | 0 | 0 |
| Chloride high  | 13 (2) | 0 | 0 | 0 | 0 |
| Bicarbonate low | 8 (2) | 0 | 0 | 0 | 0 |
| Creatinine increased | 7 (4) | 1 (1) | 0 | 0 | 0 |
| GGT increased | 3 (3) | 3 (2) | 1 (1) | 0 | 0 |
| Monocyte count increased | 7 (5) | 0 | 0 | 0 | 0 |
| MCV decrease | 6 (5) | 0 | 0 | 0 | 0 |
| MCV increase | 6 (4) | 0 | 0 | 0 | 0 |
| CRP increased | 4 (2) | 0 | 0 | 0 | 0 |
| Eosinophils decreased | 4 (2) | 0 | 0 | 0 | 0 |
| Alkaline phosphatase increased  | 4 (4) | 0 | 0 | 0 | 0 |
| Lymphocyte count increased | 0 | 2 (2) | 1 (1) | 0 | 0 |
| Phosphate high | 3 (2) | 0 | 0 | 0 | 0 |
| ALT decreased | 3 (2) | 0 | 0 | 0 | 0 |
| Creatinine decreased | 3 (1) | 0 | 0 | 0 | 0 |
| Weight loss | 2 (2) | 1 (1) | 0 | 0 | 0 |
| Elevated bicarbonate levels | 2 (1) | 0 | 0 | 0 | 0 |
| Mean corpuscular volume decreased | 2 (1) | 0 | 0 | 0 | 0 |
| Monocytes low | 2 (1) | 0 | 0 | 0 | 0 |
| Haemoglobin increased | 2 (1) | 0 | 0 | 0 | 0 |
| MCHC high | 2 (1) | 0 | 0 | 0 | 0 |
| C-Reactive protein increase | 1 (1) | 1 (1) | 0 | 0 | 0 |
| Alkaline phosphatase decrease | 1 (1) | 0 | 0 | 0 | 0 |
| Cholesterol high | 0  | 1 (1) | 0 | 0 | 0 |
| INR increased | 0 | 0 | 1 (1) | 0 | 0 |
| Basophils high | 1 (1) | 0 | 0 | 0 | 0 |
| Urine output decreased | 0 | 0 | 1 (1) | 0 | 0 |
| Lactate dehydrogenase increased | 1 (1) | 0 | 0 | 0 | 0 |
| Haemoglobin low | 1 (1) | 0 | 0 | 0 | 0 |
| Mean cell haemoglobin decrease | 1 (1) | 0 | 0 | 0 | 0 |
| Chloride increased | 1 (1) | 0 | 0 | 0 | 0 |
| High ferritin  | 0 | 1 (1) | 0 | 0 | 0 |
| Thrombin time increased | 1 (1) | 0 | 0 | 0 | 0 |
| Increased urine output | 0 | 1 (1) | 0 | 0 | 0 |
| Blood prolactin abnormal | 1 (1) | 0 | 0 | 0 | 0 |
| Metabolism and nutrition disorders |
| Hypokalaemia  | 23 (9) | 2 (2) | 5 (5) | 0 | 0 |
| Hypoalbuminemia  | 11 (8) | 4 (4) | 1 (1) | 0 | 0 |
| Hyponatremia | 9 (7) | 0 | 2 (2) | 0 | 0 |
| Hypomagnesemia  | 14 (8) | 0 | 0 | 0 | 0 |
| Hypophosphatemia  | 3 (2) | 4 (4) | 1 (1) | 0 | 0 |
| Hypernatremia  | 5 (5) | 2 (2) | 0 | 0 | 0 |
| Anorexia  | 3 (2) | 0 | 0 | 0 | 0 |
| Blood glucose increased | 2 (1) | 0 | 0 | 0 | 0 |
| Hypocalcaemia  | 2 (2) | 0 | 0 | 0 | 0 |
| Hyperphosphatemia  | 2 (1) | 0 | 0 | 0 | 0 |
| Hyperuricemia  | 2 (2) | 0 | 0 | 0 | 0 |
| Dehydration  | 0 | 0 | 2 (2) | 0 | 0 |
| Chloride levels decreased | 1 (1) | 0 | 0 | 0 | 0 |
| Increased thirst | 0 | 0 | 1 (1) | 0 | 0 |
| Hyperglycaemia  | 0 | 1 (1) | 0 | 0 | 0 |
| Weight gain | 1 (1) | 1(1) | 0 | 0 | 0 |
| Hyperkalaemia  | 1 (1) | 0 | 0 | 0 | 0 |
| Hypertriglyceridemia  | 0 | 0 | 1 (1) | 0 | 0 |
| Musculoskeletal and connective tissue disorders |
| Muscle weakness left-sided | 1 (1) | 2 (2) | 2 (2) | 0 | 0 |
| Pain in extremity | 1 (1) | 2 (2) | 1 (1) | 0 | 0 |
| Generalised muscle weakness | 0 | 1 (1) | 2 (2) | 0 | 0 |
| Back pain | 2 (2) | 0 | 1 (1) | 0 | 0 |
| Neck pain | 0 | 1 (1) | 1 (1) | 0 | 0 |
| Muscle weakness lower limb | 0 | 0 | 1 (1) | 0 | 0 |
| Flank pain | 0 | 1 (1) | 0 | 0 | 0 |
| Pain in right shoulder | 0 | 1 (1) | 0 | 0 | 0 |
| Myalgia  | 0  | 1 (1) | 0 | 0 | 0 |
| Muscle weakness right-sided | 0 | 0 | 1 (1) | 0 | 0 |
| Muscle weakness trunk | 0 | 1 (1) | 0 | 0 | 0 |
| Joint range of motion decreased | 1 (1) | 0 | 0 | 0 | 0 |
| Nervous system disorders |
| Headache | 9 (6) | 4 (3) | 4 (4) | 0 | 0 |
| Lethargy  | 5 (4) | 6 (5) | 0 | 0 | 0 |
| Dysarthria  | 2 (2) | 2 (2) | 3 (3) | 0 | 0 |
| Seizure | 0 | 4 (4) | 2 (1) | 0 | 0 |
| Hydrocephalus  | 0 | 1 (1) | 1 (1) | 1 (1) | 0 |
| Ataxia  | 1 (1) | 1 (1) | 1 (1) | 0 | 0 |
| Facial muscle weakness | 1 (1) | 1 (1) | 0 | 0 | 0 |
| Paraesthesia  | 2 (2) | 0 | 0 | 0 | 0 |
| Hemiplegia | 0 | 0 | 1 (1) | 0 | 0 |
| Spasticity  | 0 | 1 (1) | 0 | 0 | 0 |
| Sleep disturbance – wakes early | 1 (1) | 0 | 0 | 0 | 0 |
| Paraplegia  | 0 | 0 | 1 (1) | 0 | 0 |
| Bladder emptying disorder | 0 | 0 | 1 (1) | 0 | 0 |
| Memory impairment | 0 | 1 (1) | 0 | 0 | 0 |
| Dysesthesia  | 1 (1) | 0 | 0 | 0 | 0 |
| Tremor | 0 | 0 | 1 (1) | 0 | 0 |
| Imbalance | 1 (1) | 0 | 0 | 0 | 0 |
| Somnolence | 0 | 0 | 1 (1) | 0 | 0 |
| Spinal cord injury | 0 | 0 | 1 (1) | 0 | 0 |
| Polydipsia  | 0 | 0 | 1 (1) | 0 | 0 |
| Dysphagia  | 0 | 1 (1) | 0 | 0 | 0 |
| Hypersomnia  | 1 (1) | 0 | 0 | 0 | 0 |
| Bowel emptying disorder | 0 | 0 | 1 (1) | 0 | 0 |
| Dysgeusia  | 1 (1) | 0 | 0 | 0 | 0 |
| Intra-tumoral haemorrhage and surrounding cerebral oedema  | 0 | 0 | 0 | 1 (1) | 0 |
| Dizziness  | 1 (1) | 0 | 0 | 0 | 0 |
| Psychiatric disorders |
| Anxiety  | 2 (2) | 2 (2) | 1 (1) | 0 | 0 |
| Insomnia  | 1 (1) | 1 (1) | 2 (1) | 0 | 0 |
| Confusion | 0 | 1 (1) | 2 (2) | 0 | 0 |
| Libido decreased | 1 (1) | 0 | 0 | 0 | 0 |
| Low mood | 1 (1) | 0 | 0 | 0 | 0 |
| Euphoria  | 0 | 1 (1) | 0 | 0 | 0 |
| Restlessness  | 0 | 1 (1) | 0 | 0 | 0 |
| Renal and urinary disorders |
| Urea increased | 15 (8) | 0 | 0 | 0 | 0 |
| Urea decreased | 13 (7) | 0 | 0 | 0 | 0 |
| Urea low | 2 (1) | 0 | 0 | 0 | 0 |
| Acute kidney injury | 1 (1) | 0 | 1 (1) | 0 | 0 |
| Urinary retention | 0 | 1 (1) | 0 | 0 | 0 |
| Urea high | 1 (1) | 0 | 0 | 0 | 0 |
| Urinary incontinence  | 0 | 1 (1) | 0 | 0 | 0 |
| Cystitis non-infective | 1 (1) | 0 | 0 | 0 | 0 |
| Polyuria  | 0 | 0 | 1 (1) | 0 | 0 |
| Bladder spasm | 0 | 1 (1) | 0 | 0 | 0 |
| Bladder perforation  | 0 | 0 | 1 (1) | 0 | 0 |
| Reproductive system and breast disorders |
| Vaginal pain | 1 (1) | 0 | 0 | 0 | 0 |
| Respiratory, thoracic and mediastinal disorders |
| Dyspnoea  | 3 (3) | 1 (1) | 7 (5) | 1 (1) | 0 |
| Cough  | 8 (6) | 0 | 0 | 0 | 0 |
| Hypoxia  | 0 | 1 (1) | 3 (3) | 0 | 0 |
| Pleural effusion  | 0  | 1 (1) | 2 (2) | 0 | 0 |
| Sore throat | 2 (2) | 0 | 0 | 0 | 0 |
| Epistaxis | 0 | 2 (2) | 0 | 0 | 0 |
| Respiratory failure | 0 | 0 | 0 | 1 (1) | 0 |
| Respiratory distress | 0 | 0 | 0 | 1 (1) | 0 |
| Pulmonary oedema  | 0 | 0 | 1 (1) | 0 | 0 |
| Runny nose | 1 (1) | 0 | 0 | 0 | 0 |
| Apnoea  | 0 | 1 (1) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders |  |  |  |  |  |
| Rash maculo-papular | 4 (4) | 0 | 1 (1) | 0 | 0 |
| Alopecia  | 1 (1) | 3 (3) | 0 | 0 | 0 |
| Pruritus  | 2 (2) | 0 | 0 | 0 | 0 |
| Itching  | 1 (1) | 0 | 0 | 0 | 0 |
| Photosensitivity  | 1 (1) | 0 | 0 | 0 | 0 |
| Skin atrophy | 0 | 1 (1) | 0 | 0 | 0 |
| Skin ulceration | 0 | 1 (1) | 0 | 0 | 0 |
| Blister on abdomen | 1 (1) | 0 | 0 | 0 | 0 |
| Rash-graft versus host disease  | 0 | 1 (1) | 0 | 0 | 0 |
| Shingles  | 0 | 1 (1) | 0 | 0 | 0 |
| Urticaria  | 1 (1) | 0 | 0 | 0 | 0 |
| Dry skin | 1 (1) | 0 | 0 | 0 | 0 |
| Vascular disorders |
| Hypertension  | 2 (2) | 2 (2) | 0 | 0 | 0 |
| Hypotension  | 1 (1) | 1 (1) | 0 | 0 | 0 |
| Flushing | 1 (1) | 0 | 0 | 0 | 0 |
| Thromboembolic event | 0 | 1 (1) | 0 | 0 | 0 |

Supplementary Table 8. Number of Adverse Events related to treatment

|  |  |
| --- | --- |
|  | Grade |
| 1 | 2 | 3 | 4 | 5 |
| Toxicity (No. events (No. patients that experienced toxicity) |
| Gastrointestinal disorders |
| Vomiting  | 1 (1) | 0 | 0 | 0 | 0 |
| Abdominal pain | 1 (1) | 0 | 0 | 0 | 0 |
| Immune system disorders |
| Allergic reaction | 0 | 1 (1) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders |
| Urticaria  | 1 (1) | 0 | 0 | 0 | 0 |